107
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA

, , , &
Pages 557-567 | Published online: 20 Sep 2017

Figures & data

Table 1 Summary of clinical data sources

Table 2 Key clinical input values

Table 3 SAE rate input values, costs referenced from IPPS FY 2016 Correction Notice,Citation21 rates from NCT00255424 and NCT00255437Citation3,Citation16

Table 4 Key cost input values

Table 5 Overall cost and cost-effectiveness results for each treatment strategy, in the overall patient population and in different baseline Hb patient subgroups

Figure 1 Tornado graphs depicting one-way sensitivity analysis outcomes for FER, FER with ESA, oral iron, and oral iron with ESA.

Notes: The high bar (dark gray) represents the effect of a 20% increase from the base case value of the indicated variable on the cost per g/dL increase in Hb (in USD). The low bar (light gray) represents the effect of a 20% decrease from the base case value of the indicated variable on the cost per g/dL increase in Hb (in USD).
Abbreviations: ESA, erythropoietin-stimulating agent; FER, ferumoxytol; Hb, hemoglobin; SAE, serious adverse event.
Figure 1 Tornado graphs depicting one-way sensitivity analysis outcomes for FER, FER with ESA, oral iron, and oral iron with ESA.